Krystal Biotech, Inc. Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross
Krystal Biotech, Inc. (KRYS) had Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross of $0 as of 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Notes › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross · last filed 2024-02-26
- 2023-12-31: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $0.00.
- 2022-12-31: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $192.00K.
- 2021-12-31: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $49.00K.
| Period end | Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-26 |
| 2022-12-31 | $192.00K 10-K · filed 2024-02-26 |
| 2021-12-31 | $49.00K 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |